杭州瑞普晨创科技

Repro-Stem Biotechnology is a clinical-stage biotechnology company specializing in regenerative medicine through its proprietary chemically induced pluripotent stem cell (CiPSC) platform. Founded by Dr. Deng Hongkui, the company focuses on developing off-the-shelf cell therapies to treat chronic diseases such as Type 1 Diabetes, Parkinson's Disease, and heart failure. Their lead program involves CiPSC-derived islet cells for insulin-dependent diabetes, which has progressed into clinical trials and demonstrated functional restoration of insulin production. The company's unique small-molecule reprogramming approach aims to overcome safety and ethical limitations associated with traditional genetic reprogramming methods. Repro-Stem is positioned as a leader in the next generation of stem cell-based therapeutics in China.